PPARG and Alzheimer disease: These findings indicate the need for additional investigations into PPARγ agonists, such as the metabolite of PGD2, 15-PGJ2, for the treatment of AD; a novel series of PPARγ agonists was recently explored in 3xTgAD animals to show attenuated inflammation [157].